Work

A Phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumors

Year: 2007

Type: article

Study design: Clinical Trial

Source: Molecular Cancer Therapeutics

Authors: Heather M. Shaw, R. Molife, Vasilios Karavasilis, Teng Jin Ong, Laura Tate, Peter C.C. Fong, T.A. Yap, Rohit Lal, Catherine M. Ludwig, E. Brendel, Olaf Christensen, Johann S. de Bono

Institution: Royal Marsden Hospital

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2197868217

FWCI:

Cites:

Cited by:

Related to: 10